Literature DB >> 35314376

Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation.

Sagar S Patel1, Kwang Woo Ahn2, Manoj Khanal3, Caitrin Bupp4, Mariam Allbee-Johnson3, Navneet S Majhail5, Betty K Hamilton6, Seth J Rotz7, Hasan Hashem8, Amer Beitinjaneh9, Hillard M Lazarus10, Maxwell M Krem11, Tim Prestidge12, Neel S Bhatt13, Akshay Sharma14, Shahinaz M Gadalla15, Hemant S Murthy16, Larisa Broglie17, Taiga Nishihori18, César O Freytes19, Gerhard C Hildebrandt20, Usama Gergis21, Sachiko Seo22, Baldeep Wirk23, Marcelo C Pasquini3, Bipin N Savani24, Mohamed L Sorror25, Edward A Stadtmauer26, Saurabh Chhabra27.   

Abstract

Noninfectious pulmonary toxicity (NPT), a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), includes idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP), with an overall incidence ranging from 1% to 15% in different case series and a variable mortality rate. A registry study of the epidemiology and outcomes of NPT after alloHCT has not been conducted to date. The primary objective of the present study was to assess the incidence of and risk factors for IPS, DAH, and COP; the secondary objective was to assess overall survival (OS) in patients developing NPT. This retrospective study included adult patients who underwent alloHCT between 2008 and 2017 and reported to the Center for International Blood and Marrow Transplant Research. Multivariable Cox proportional hazards regression models were developed to identify the risk factors for development of NPT and for OS, by including pretransplantation clinical variables and time-dependent variables of neutrophil and platelet recovery, and acute graft-versus-host disease (GVHD) post-transplantation. This study included 21,574 adult patients, with a median age of 55 years. According to the HCT Comorbidity Index (HCT-CI), 24% of the patients had moderate pulmonary comorbidity and 15% had severe pulmonary comorbidity. The cumulative incidence of NPT at 1 year was 8.1% (95% confidence interval [CI], 7.7% to 8.5%). Individually, the 1-year cumulative incidences of IPS, DAH, and COP were 4.9% (95% CI, 4.7% to 5.2%), 2.1% (95% CI, 1.9% to 2.3%), and .7% (95% CI, .6% to .8%), respectively. Multivariable analysis showed that severe pulmonary comorbidity, grade II-IV acute GVHD, mismatched unrelated donor and cord blood transplantation, and HCT-CI score ≥1 significantly increased the risk of NPT. In contrast, alloHCT performed in 2014 or later, non-total body irradiation (TBI)- and TBI-based nonmyeloablative conditioning and platelet recovery were associated with a decreased risk. In a landmark analysis at day+100 post-transplantation, the risk of DAH was significantly lower in patients who had platelet recovery by day +100. Multivariable analysis for OS demonstrated that NPT significantly increased the mortality risk (hazard ratio, 4.2; P < .0001).
Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; Cryptogenic organizing pneumonia; Diffuse alveolar hemorrhage; Idiopathic pneumonia syndrome; Noninfectious pulmonary toxicity

Mesh:

Year:  2022        PMID: 35314376      PMCID: PMC9197865          DOI: 10.1016/j.jtct.2022.03.015

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  36 in total

1.  Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation.

Authors:  H Nakasone; M Onizuka; N Suzuki; N Fujii; S Taniguchi; K Kakihana; H Ogawa; K Miyamura; T Eto; H Sakamaki; H Yabe; Y Morishima; K Kato; R Suzuki; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

2.  Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients.

Authors:  J Keates-Baleeiro; P Moore; T Koyama; B Manes; C Calder; H Frangoul
Journal:  Bone Marrow Transplant       Date:  2006-07-03       Impact factor: 5.483

Review 3.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

4.  Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.

Authors:  Bekele Afessa; Ayalew Tefferi; Mark R Litzow; Steve G Peters
Journal:  Am J Respir Crit Care Med       Date:  2002-09-25       Impact factor: 21.405

5.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

6.  Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.

Authors:  Gregory A Yanik; Mary M Horowitz; Daniel J Weisdorf; Brent R Logan; Vincent T Ho; Robert J Soiffer; Shelly L Carter; Juan Wu; John R Wingard; Nancy L Difronzo; James L Ferrara; Sergio Giralt; David K Madtes; Rebecca Drexler; Eric S White; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

Review 7.  Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Anne Bergeron; Guang-Shing Cheng
Journal:  Clin Chest Med       Date:  2017-09-19       Impact factor: 2.878

8.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

9.  Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation. A postmortem study.

Authors:  C Agustí; J Ramirez; C Picado; A Xaubet; E Carreras; E Ballester; A Torres; C Battochia; R Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

10.  Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.

Authors:  Takahiro Fukuda; Robert C Hackman; Katherine A Guthrie; Brenda M Sandmaier; Michael Boeckh; Michael B Maris; David G Maloney; H Joachim Deeg; Paul J Martin; Rainer F Storb; David K Madtes
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

View more
  1 in total

1.  Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation.

Authors:  Yuya Kishida; Naoki Shingai; Konan Hara; Makiko Yomota; Chika Kato; Satoshi Sakai; Yasuhiro Kambara; Yuya Atsuta; Ryosuke Konuma; Atsushi Wada; Daisuke Murakami; Shiori Nakashima; Yusuke Uchibori; Daishi Onai; Atsushi Hamamura; Akihiko Nishijima; Takashi Toya; Hiroaki Shimizu; Yuho Najima; Takeshi Kobayashi; Hisashi Sakamaki; Kazuteru Ohashi; Noriko Doki
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.